Delix Therapeutics raised $100 million in a Series C to build out its neuroplastogen and psychiatric pipeline, aiming to accelerate development in a crowded neuropsychiatry investment cycle. The round underscores investor interest in next-generation mechanisms beyond traditional antidepressants and stimulants. The financing also reflects a broader industry push toward compounds designed to rapidly influence neuroplasticity pathways, with Delix positioning itself to compete for clinical momentum in psychiatric and mental health indications.